AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 350506 — intervention group
Group type: EXPERIMENTAL
Intervention: New cream vehicle for flurandrenolide
Number of subjects: 0
Study 350506 — intervention group
Group type: COMPARATOR
Intervention: Previous formulation
Number of subjects: 0
Study 30764651 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 203
Study 30764651 — intervention group
Group type: COMPARATOR
Intervention: No decision aid (control group)
Number of subjects: 203
Study 30764651 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention preference
Number of subjects: 203
Study 30764651 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery preference
Number of subjects: 203
Study 30390639 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention via loudspeakers from self-selected genres
Number of subjects: 304
Study 30390639 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without music (Control)
Number of subjects: 304
Study 27058405 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched environmental activities programme
Number of subjects: 103
Study 27058405 — intervention group
Group type: COMPARATOR
Intervention: Usual ward activity
Number of subjects: 103
Study 24675014 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold
Number of subjects: 2000
Study 24675014 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion threshold
Number of subjects: 2000
Study 22318191 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg long-acting methylphenidate
Number of subjects: 21
Study 20973316 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g as slurry with 250 ml of water)
Number of subjects: 12
Study 20973316 — intervention group
Group type: COMPARATOR
Intervention: Control (250 mL of water)
Number of subjects: 12
Study 17722615 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 55
Study 17722615 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg/day
Number of subjects: 55
Study 15692125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg/d
Number of subjects: 242
Study 15692125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 12829593 — intervention group
Group type: EXPERIMENTAL
Intervention: +4 and +18 (in children younger than 10 years)
Number of subjects: 700
Study 12829593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (boys older than 9 years, boys aged 1-9 years without +18, girls older than 9 years without +18)
Number of subjects: 700
Study 12829593 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls aged 1-9 years with +18
Number of subjects: 700
Study 12829593 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, +4, +18 (independent indicators from multivariate analysis)
Number of subjects: 700
Study 10736978 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and ATIII (Group A)
Number of subjects: 2
Study 10736978 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus placebo (Group B)
Number of subjects: 2
Study 8859935 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 2.5 mg p.o. + placebo i.v. (day 1) and enalapril 2.5 mg p.o. (day 2)
Number of subjects: 48
Study 8859935 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril 2 mg orally (p.o.) + placebo intravenously (i.v.) (day 1) and perindopril 2 mg p.o. (day 2)
Number of subjects: 48
Study 8859935 — intervention group
Group type: COMPARATOR
Intervention: placebo p.o. + perindopril at 0.167 mg i.v. (day 1) and perindopril 2 mg p.o. (day 2)
Number of subjects: 48
Study 8859935 — intervention group
Group type: COMPARATOR
Intervention: placebo p.o. + placebo i.v. (day 1) and placebo p.o. (day 2)
Number of subjects: 48
Study 8859935 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 2.5 mg p.o.
Number of subjects: 48
Study 8859935 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril 2 mg p.o.
Number of subjects: 48
Study 8859935 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril therapy
Number of subjects: 48
Study 1509399 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid crystal contact thermography (LCCT)
Number of subjects: 194
Study 1509399 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of plasma D-dimer (DD)
Number of subjects: 194
Study 1509399 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ascending phlebography
Number of subjects: 194
Study 6362110 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy as the primary form of treatment (Group B)
Number of subjects: 40
Study 6362110 — intervention group
Group type: COMPARATOR
Intervention: Conventional management using medical therapy followed by trabeculectomy only in unsuccessful cases (Group A)
Number of subjects: 40
Study 6362110 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy (Group B)
Number of subjects: 40
Study 30403772 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking breaks (5 minutes of self-paced light walking every 30 minutes)
Number of subjects: 60
Study 30403772 — intervention group
Group type: COMPARATOR
Intervention: Standing breaks (5 minutes of standing every 30 minutes)
Number of subjects: 60
Study 30403772 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (continuous sitting for 7.5 hours)
Number of subjects: 60
Study 29941019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-sensory sacral neuromodulation (SNM)
Number of subjects: 90
Study 29941019 — intervention group
Group type: COMPARATOR
Intervention: SHAM stimulation
Number of subjects: 90
Study 26728982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Shaoyao Shujin tablet
Number of subjects: 276
Study 26728982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Shaoyao Shujin tablet
Number of subjects: 276
Study 26728982 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 276
Study 24501370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter volume in the hippocampus
Number of subjects: 0
Study 24501370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter volume in the dorsolateral prefrontal cortex
Number of subjects: 0
Study 22295811 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Nimodipine (Group A)
Number of subjects: 100
Study 22295811 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine alone (Group B)
Number of subjects: 100
Study 20929121 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Guchong Recipe (SGR)
Number of subjects: 78
Study 20929121 — intervention group
Group type: COMPARATOR
Intervention: Kunning Oral Liquid (Control)
Number of subjects: 78
Study 18037734 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10‐20 mg/day)
Number of subjects: 58
Study 18037734 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 16118591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer (PED)
Number of subjects: 85
Study 16118591 — intervention group
Group type: EXPERIMENTAL
Intervention: Minutes (MIN)
Number of subjects: 85
Study 16118591 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 85
Study 12384805 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL plus interleukin‐2 (IL‐2) for 2 months
Number of subjects: 88
Study 12384805 — intervention group
Group type: COMPARATOR
Intervention: IL‐2 only
Number of subjects: 88
Study 9507965 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach-to-grasp movements involving living-thing pairs
Number of subjects: 0
Study 9507965 — intervention group
Group type: COMPARATOR
Intervention: Reach-to-grasp movements involving non-living things
Number of subjects: 0
Study 7921394 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser vaporization of endometriosis
Number of subjects: 44
Study 7921394 — intervention group
Group type: COMPARATOR
Intervention: No carbon dioxide laser vaporization of endometriosis (Control)
Number of subjects: 44
Study 3041818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 125
Study 3041818 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 125
Study 30971205 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCELS-website (mobile-optimized technology platform)
Number of subjects: 480
Study 30971205 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCELS-health coaching
Number of subjects: 480
Study 30971205 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCELS-website and health coaching
Number of subjects: 480
Study 30971205 — intervention group
Group type: COMPARATOR
Intervention: Print booklet
Number of subjects: 480
Study 30121876 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week parenting intervention
Number of subjects: 270
Study 26712905 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (docetaxel 75 mg/m² day 1, cisplatin 75 mg/m² day 1, fluorouracil 300 mg/m²/day over days 1-14) before gastrectomy (arm A)
Number of subjects: 70
Study 26712905 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (docetaxel 75 mg/m² day 1, cisplatin 75 mg/m² day 1, fluorouracil 300 mg/m²/day over days 1-14) after gastrectomy (arm B)
Number of subjects: 70
Study 24585161 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bedside pressure mapping (CBPM) device
Number of subjects: 422
Study 24585161 — intervention group
Group type: COMPARATOR
Intervention: Control group (without CBPM)
Number of subjects: 422
Study 22883507 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 17603
Study 22883507 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17603
Study 20382638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 0
Study 20382638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST) for HIV-infected individuals
Number of subjects: 0
Study 18097989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enriched learning method (MH(2))
Number of subjects: 33
Study 18097989 — intervention group
Group type: COMPARATOR
Intervention: Standard learning method (MH(1))
Number of subjects: 33
Study 18097989 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied (AB)
Number of subjects: 33
Study 15613622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 8
Study 15613622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12065268 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE programme (intervention group)
Number of subjects: 8430
Study 12065268 — intervention group
Group type: COMPARATOR
Intervention: Existing sex education (control programme)
Number of subjects: 8430
Study 9661555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine 60 mg administered before induction of anesthesia (Group 1)
Number of subjects: 98
Study 9661555 — intervention group
Group type: COMPARATOR
Intervention: Epidural ketamine 60 mg administered after the parietal peritoneum was closed (Group 2)
Number of subjects: 98
Study 8123485 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 13
Study 8123485 — intervention group
Group type: COMPARATOR
Intervention: Control (unprotected cycles)
Number of subjects: 13
Study 2598905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h nap taken at 0200 h
Number of subjects: 6
Study 2598905 — intervention group
Group type: COMPARATOR
Intervention: 300 mg caffeine ingested at 2315 h
Number of subjects: 6
Study 2598905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1103897 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg AR-DF 26 (gliquidone) - oral application
Number of subjects: 10
Study 1103897 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. application of AR-DF 26
Number of subjects: 10
Study 1103897 — intervention group
Group type: EXPERIMENTAL
Intervention: oral application of AR-DF 26
Number of subjects: 10
Study 1103897 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. and oral application of AR-DF 26
Number of subjects: 10
Study 6927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra prompt condition (color-coded laces)
Number of subjects: 20
Study 6927657 — intervention group
Group type: COMPARATOR
Intervention: No extra prompt condition (naturalistic shoe)
Number of subjects: 20
Study 6927657 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up procedure (choice between color prompt and position cue)
Number of subjects: 20
Study 31283892 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP dentifrice
Number of subjects: 0
Study 31283892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination CPP-ACP-cranberry dentifrice
Number of subjects: 0
Study 31283892 — intervention group
Group type: COMPARATOR
Intervention: Fluoride control dentifrice
Number of subjects: 0
Study 31404817 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of piano training
Number of subjects: 0
Study 31404817 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of videogame training
Number of subjects: 0
Study 31404817 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study 28657699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low abrasivity aluminum trioxide/STP dentifrice (RDA40)
Number of subjects: 95
Study 28657699 — intervention group
Group type: COMPARATOR
Intervention: Ultra‐low abrasivity dentifrice (5% STP only; RDA13)
Number of subjects: 95
Study 28657699 — intervention group
Group type: COMPARATOR
Intervention: Moderate abrasivity fluoride dentifrice (RDA80)
Number of subjects: 95
Study 28657699 — intervention group
Group type: COMPARATOR
Intervention: Higher abrasivity whitening dentifrice (RDA142)
Number of subjects: 95
Study 25677596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.1 mg/kg
Number of subjects: 50
Study 25677596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 50
Study 25677596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (both doses)
Number of subjects: 50
Study 23395356 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal add-on IOL group
Number of subjects: 34
Study 23395356 — intervention group
Group type: COMPARATOR
Intervention: Multifocal PC IOL group
Number of subjects: 34
Study 20642488 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg i.v.-ibuprofen every 6 hours
Number of subjects: 319
Study 20642488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 19384673 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin flexible dosing (5-10 mg)
Number of subjects: 0
Study 19384673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg sustained release (SR)
Number of subjects: 0
Study 19384673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (assumed to be comparable to no treatment)
Number of subjects: 0
Study 17197286 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injury to the endometrium prior to controlled ovarian stimulation
Number of subjects: 0
Study 17197286 — intervention group
Group type: COMPARATOR
Intervention: Control (no local injury)
Number of subjects: 0
Study 15100637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (home program of vestibular habituation head movement exercises)
Number of subjects: 0
Study 11336584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy (bismuth compound plus metronidazole, tetracycline or amoxycillin) for 2 weeks
Number of subjects: 0
Study 11336584 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (PPI)-based triple therapy for 1 week
Number of subjects: 0
Study 11336584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC)-based triple therapy (PPI or RBC plus any two of metronidazole, amoxycillin, and clarithromycin) for 1 week
Number of subjects: 0
Study 11336584 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC-triple therapy for resistant strains
Number of subjects: 0
Study 11336584 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment regimens
Number of subjects: 0
Study 9609422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal laser lithotripsy (ILL)
Number of subjects: 60
Study 9609422 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 60
Study 7819706 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU of hCG, injected subcutaneously on days 3, 6, 9, and 12 after transvaginal aspiration (TVA)
Number of subjects: 77
Study 7819706 — intervention group
Group type: COMPARATOR
Intervention: 50 mg daily injections of intramuscular progesterone from days 2 to 14 after TVA
Number of subjects: 77
Study 2891940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine (10 mg/kg bodyweight daily)
Number of subjects: 16
Study 2891940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31442495 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-μg patch (epicutaneous immunotherapy for peanut allergy)
Number of subjects: 0
Study 31442495 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 27668978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 40
Study 27668978 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 40
Study 27668978 — intervention group
Group type: EXPERIMENTAL
Intervention: US combined with MRI
Number of subjects: 40
Study 27668978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement among 3 readers
Number of subjects: 40
Study 27668978 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement among 3 readers
Number of subjects: 40
Study 26802884 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach (closure of the perforation with endoclips and SEMS)
Number of subjects: 23
Study 26802884 — intervention group
Group type: COMPARATOR
Intervention: Surgical repair (hepaticojejunostomy, suture of the perforation or duodenal suture)
Number of subjects: 23
Study 23179351 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg nickel chloride
Number of subjects: 240
Study 23179351 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/kg nickel chloride
Number of subjects: 240
Study 23179351 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/kg nickel chloride
Number of subjects: 240
Study 23179351 — intervention group
Group type: COMPARATOR
Intervention: Control diet (corn-soybean basal diet)
Number of subjects: 240
Study 21647813 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-specific training
Number of subjects: 45
Study 21647813 — intervention group
Group type: EXPERIMENTAL
Intervention: SIL-specific training
Number of subjects: 45
Study 21647813 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP technique
Number of subjects: 45
Study 21647813 — intervention group
Group type: EXPERIMENTAL
Intervention: SIL-specific simulator training
Number of subjects: 45
Study 21647813 — intervention group
Group type: EXPERIMENTAL
Intervention: SIL training using STR instruments
Number of subjects: 45
Study 19637959 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine replacement of peripheral intravenous catheters at 72-96 hours
Number of subjects: 316
Study 19637959 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring of peripheral intravenous catheters (replacement only on clinical indication)
Number of subjects: 316
Study 16784946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranio-caudal direction (group A)
Number of subjects: 203
Study 16784946 — intervention group
Group type: COMPARATOR
Intervention: Caudo-cranial direction (group B)
Number of subjects: 203
Study 15282457 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of protamine sulphate (25 mg/h for 6 hours)
Number of subjects: 300
Study 15282457 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 300
Study 10325668 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GR) 1 mg
Number of subjects: 13
Study 10325668 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (PCh) 10 mg
Number of subjects: 13
Study 9156935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatographic fraction ultrafiltrate of plasma (substances in the first peak)
Number of subjects: 20
Study 9156935 — intervention group
Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 20
Study 1680533 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (8 mg)
Number of subjects: 0
Study 1680533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg)
Number of subjects: 0
Study 1680533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6412508 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin-V, 55 mg/kg/day for two days
Number of subjects: 103
Study 6412508 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-V, 55 mg/kg/day for seven days
Number of subjects: 103
Study 31725362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LL-BFR) training (20-35% of one-repetition maximum)
Number of subjects: 55
Study 31725362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance training (70-85% of one-repetition maximum)
Number of subjects: 55
Study 31725362 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (CON) group
Number of subjects: 55
Study 29389472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU) therapy for 8 weeks
Number of subjects: 45
Study 29389472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 26998820 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 90
Study 26998820 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum EBNA‐1 IgG levels
Number of subjects: 90
Study 25114127 — intervention group
Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin) 1 to 300 mg single dose
Number of subjects: 40
Study 25114127 — intervention group
Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin) 10 to 150 mg once daily for 3 days
Number of subjects: 40
Study 25114127 — intervention group
Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin) with high fat food intake
Number of subjects: 40
Study 25114127 — intervention group
Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin)
Number of subjects: 40